Y F van der Heijden1, F Karim2, G Mufamadi3, L Zako3, T Chinappa3, B E Shepherd4, F Maruri1, M-Y S Moosa5, T R Sterling1, A S Pym2. 1. Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. 2. KwaZulu-Natal Research Institute for TB and HIV, Durban. 3. eThekwini Municipality, Durban, South Africa. 4. Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. 5. Department of Infectious Diseases, Division of Internal Medicine, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Abstract
SETTING: A large tuberculosis (TB) clinic in Durban, South Africa. OBJECTIVE: To determine the association between isoniazid (INH) monoresistant TB and treatment outcomes. DESIGN: We performed a retrospective longitudinal study of patients seen from 2000 to 2012 to compare episodes of INH-monoresistant TB with those of drug-susceptible TB using logistic regression with robust standard errors. INH-monoresistant TB was treated with modified regimens. RESULTS: Among 18 058 TB patients, there were 19 979 TB episodes for which drug susceptibility testing was performed. Of these, 557 were INH-monoresistant and 16 311 were drug-susceptible. Loss to follow-up, transfer, and human immunodeficiency virus (HIV) co-infection (41% had known HIV status) were similar between groups. INH-monoresistant episodes were more likely to result in treatment failure (4.1% vs. 0.6%, P < 0.001) and death (3.2% vs. 1.8%, P = 0.01) than drug-susceptible episodes. After adjustment for age, sex, race, retreatment status, and disease site, INH-monoresistant episodes were more likely to have resulted in treatment failure (OR 6.84, 95%CI 4.29-10.89, P < 0.001) and death (OR 1.81, 95%CI 1.11-2.95, P = 0.02). CONCLUSION: INH monoresistance was associated with worse clinical outcomes than drug-susceptible TB. Our findings support the need for rapid diagnostic tests for INH resistance and improved treatment regimens for INH-monoresistant TB.
SETTING: A large tuberculosis (TB) clinic in Durban, South Africa. OBJECTIVE: To determine the association between isoniazid (INH) monoresistant TB and treatment outcomes. DESIGN: We performed a retrospective longitudinal study of patients seen from 2000 to 2012 to compare episodes of INH-monoresistant TB with those of drug-susceptible TB using logistic regression with robust standard errors. INH-monoresistant TB was treated with modified regimens. RESULTS: Among 18 058 TB patients, there were 19 979 TB episodes for which drug susceptibility testing was performed. Of these, 557 were INH-monoresistant and 16 311 were drug-susceptible. Loss to follow-up, transfer, and human immunodeficiency virus (HIV) co-infection (41% had known HIV status) were similar between groups. INH-monoresistant episodes were more likely to result in treatment failure (4.1% vs. 0.6%, P < 0.001) and death (3.2% vs. 1.8%, P = 0.01) than drug-susceptible episodes. After adjustment for age, sex, race, retreatment status, and disease site, INH-monoresistant episodes were more likely to have resulted in treatment failure (OR 6.84, 95%CI 4.29-10.89, P < 0.001) and death (OR 1.81, 95%CI 1.11-2.95, P = 0.02). CONCLUSION: INH monoresistance was associated with worse clinical outcomes than drug-susceptible TB. Our findings support the need for rapid diagnostic tests for INH resistance and improved treatment regimens for INH-monoresistant TB.
Authors: Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins Journal: N Engl J Med Date: 2010-09-01 Impact factor: 91.245
Authors: Dick Menzies; Andrea Benedetti; Anita Paydar; Sarah Royce; Pai Madhukar; William Burman; Andrew Vernon; Christian Lienhardt Journal: PLoS Med Date: 2009-09 Impact factor: 11.069
Authors: Kathrin Zürcher; Marie Ballif; Lukas Fenner; Sonia Borrell; Peter M Keller; Joachim Gnokoro; Olivier Marcy; Marcel Yotebieng; Lameck Diero; E Jane Carter; Neesha Rockwood; Robert J Wilkinson; Helen Cox; Nicholas Ezati; Alash'le G Abimiku; Jimena Collantes; Anchalee Avihingsanon; Kamon Kawkitinarong; Miriam Reinhard; Rico Hömke; Robin Huebner; Sebastien Gagneux; Erik C Böttger; Matthias Egger Journal: Lancet Infect Dis Date: 2019-02-08 Impact factor: 25.071
Authors: Argita D Salindri; Rose-Marie F Sales; Lauren DiMiceli; Marcos C Schechter; Russell R Kempker; Matthew J Magee Journal: Ann Am Thorac Soc Date: 2018-03
Authors: Andreas Diacon; Sachiko Miyahara; Rodney Dawson; Xin Sun; Evelyn Hogg; Kathleen Donahue; Michael Urbanowski; Veronique De Jager; Courtney V Fletcher; Richard Hafner; Susan Swindells; William Bishai Journal: Lancet Microbe Date: 2020-06-08
Authors: Margaretha de Vos; Lesley Scott; Anura David; Andre Trollip; Harald Hoffmann; Sophia Georghiou; Sergio Carmona; Morten Ruhwald; Wendy Stevens; Claudia M Denkinger; Samuel G Schumacher Journal: J Clin Microbiol Date: 2021-02-18 Impact factor: 5.948
Authors: Andrew F Auld; Andrew D Kerkhoff; Yasmeen Hanifa; Robin Wood; Salome Charalambous; Yuliang Liu; Tefera Agizew; Anikie Mathoma; Rosanna Boyd; Anand Date; Ray W Shiraishi; George Bicego; Unami Mathebula-Modongo; Heather Alexander; Christopher Serumola; Goabaone Rankgoane-Pono; Pontsho Pono; Alyssa Finlay; James C Shepherd; Tedd V Ellerbrock; Alison D Grant; Katherine Fielding Journal: PLoS Med Date: 2021-09-07 Impact factor: 11.069
Authors: Anthony D Harries; Yan Lin; Ajay M V Kumar; Srinath Satyanarayana; Kudakwashe C Takarinda; Riitta A Dlodlo; Rony Zachariah; Piero Olliaro Journal: F1000Res Date: 2018-07-05
Authors: Collins Timire; Kudakwashe C Takarinda; Anthony D Harries; Herbert Mutunzi; Barbara Manyame-Murwira; Ajay M V Kumar; Charles Sandy Journal: Trans R Soc Trop Med Hyg Date: 2018-06-01 Impact factor: 2.184